Captisol, a Ligand technology

Captisol, a Ligand technology


Company description

Ligand-owned, Captisol® was invented in 1990 by scientists at the University of Kansas Higuchi Biosciences Center for use in drug development and formulation.

The Captisol® technology is used to address the limitations of currently marketed drugs. FDA-approved, Captisol-enabled® medications are marketed by: Pfizer, Bristol-Myers Squibb and Baxter International. Captisol® also has License and Supply Agreements (LSAs) in place with a number of pharmaceutical companies worldwide with Captisol-enabled® product candidates. Routes of administration investigated include parenteral, oral, ophthalmic, nasal, topical, oral, and inhalation.

Captisol® is a patent protected, uniquely modified cyclodextrin, whose chemical structure was rationally designed to enable the creation of new products by significantly improving solubility, stability, bioavailability and dosing of active pharmaceutical ingredients (APIs).

Quick facts

Sales markets UK; Western Europe; Eastern Europe; Middle East; Asia; Australia; North America; Africa; Central/South America
Primary business activity Service
Affiliated categories: Biotechnology and related specialities |Biopharmaceuticals |Excipients More

Recently at

30 apr 2019

CPhI North America 2019

30 April - 2 May 2019 Chicago, USA We were at stand 2452 See our Exhibitor Profile   See full Exhibitor List

Categories affiliated with Captisol, a Ligand technology

Captisol, a Ligand technology

Contact information




View all contact information